Analyst Starts Coverage on Twist Bioscience with Optimism; Check Out Tuesday's Top 5 Initiations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Should l Buy MBX?
Source: Benzinga
Analyst Ratings Initiations: Mizuho analyst John Roberts initiated coverage on Qnity Electronics with an Outperform rating and a price target of $110, while B. Riley Securities analyst Griffin Boss rated Phoenix Education Partners as a Buy with a target of $60.
Additional Analyst Coverage: TD Cowen analyst Tyler Van Buren initiated coverage on MBX Biosciences with a Buy rating, and B. Riley's Hal Goetsch rated Antalpha Platform Holding as a Buy with a target of $14.
Twist Bioscience Rating: Stephens & Co. analyst Steven Etoch initiated coverage on Twist Bioscience Corporation with an Overweight rating and a price target of $41.
Current Stock Prices: As of Monday, Qnity Electronics closed at $97.00, Phoenix Education at $36.00, MBX Biosciences at $20.61, Antalpha Platform at $10.81, and Twist Bioscience at $31.57.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MBX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MBX
Wall Street analysts forecast MBX stock price to rise
8 Analyst Rating
7 Buy
0 Hold
1 Sell
Strong Buy
Current: 38.000
Low
31.97
Averages
59.33
High
80.00
Current: 38.000
Low
31.97
Averages
59.33
High
80.00
About MBX
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analyst Target Prices Indicate Potential for Pharmaceuticals ETF
- ETF Upside Potential: The iShares U.S. Pharmaceuticals ETF (IHE) has an implied analyst target price of $96.28 per unit, while trading at $86.15, indicating an 11.76% upside, reflecting market optimism about the ETF's future performance.
- MBX Stock Analysis: MBX BIOSCIENCES INC (MBX) trades at $35.83, with an analyst target price of $60.55, suggesting a potential upside of 69.01%, showcasing investor confidence in its future prospects.
- CRNX Stock Outlook: Crinetics Pharmaceuticals Inc (CRNX) has a current price of $51.32 and an analyst target of $83.46, indicating a 62.63% upside, reflecting positive market sentiment regarding its product and R&D advancements.
- XERS Investment Opportunity: Xeris Biopharma Holdings Inc (XERS) is priced at $7.14, with an analyst target of $11.14, showing a 56.05% upside, indicating analysts' optimism about its growth potential.
See More
MBX Biosciences Advances Obesity Drug Development with Strong Cash Position
- Clinical Trial Progress: MBX's Phase 2 trial demonstrated significant efficacy of canvuparatide in chronic hypoparathyroidism patients, with one-year follow-up data expected in Q2 2026, reinforcing its potential as a best-in-class therapy.
- Obesity Drug Pipeline Expansion: Data from MBX 4291, a dual GLP-1/GIP co-agonist, is anticipated in Q4 2026, showcasing potential for once-monthly dosing aimed at improving tolerability for obesity patients, addressing a critical market need.
- Strong Cash Position: As of December 31, 2025, MBX reported approximately $373.7 million in cash and equivalents, expected to fund operations into 2029, ensuring continued investment in R&D and market expansion.
- New Candidate Nominations: In 2026, MBX plans to nominate two additional obesity candidates, an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist, each designed for once-monthly dosing, further enriching its obesity treatment pipeline.
See More
MBX Biosciences Updates on 2026 Clinical Progress and Strong Cash Position
- Clinical Trial Progress: MBX Biosciences plans to share 12-week data for once-weekly canvuparatide in Q2 2026, which is anticipated to establish it as a best-in-class therapy for chronic hypoparathyroidism, further solidifying its market position in the endocrine sector.
- New Drug Candidate Nominations: The company expects to nominate two new obesity treatment candidates in 2026, including an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist, aimed at addressing diverse patient needs in the obesity market and driving expansion.
- Strong Cash Position: As of December 31, 2025, MBX reported preliminary unaudited cash and cash equivalents of approximately $373.7 million, which is expected to fund operations into 2029, ensuring continued investment in R&D and market expansion.
- Strategic Conference Arrangement: MBX will provide updates on its clinical programs and obesity pipeline at the J.P. Morgan Healthcare Conference on January 13, 2026, showcasing its innovative capabilities and market potential in endocrine and metabolic disorders.
See More
Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release
- Stock Surge: Monte Rosa Therapeutics Inc (NASDAQ:GLUE) shares soared 45.2% to $23.25 after announcing interim data from its Phase 1 clinical study evaluating MRT-8102, indicating strong market confidence in its research progress and potentially attracting more investor interest.
- Acquisition Rumors: Ventyx Biosciences Inc (NASDAQ:VTYX) saw a 37.5% increase to $13.82 following reports that Eli Lilly & Co (NYSE:LLY) is in advanced talks to acquire the company for over $1 billion, which may further drive market interest in biotech stocks.
- Analyst Rating: Erasca Inc (NASDAQ:ERAS) rose 17.1% to $4.25 after Piper Sandler analyst Kelsey Goodwin initiated coverage with an Overweight rating and a price target of $5, reflecting optimism about its future growth potential.
- Market Dynamics: The overall market was mixed, with the Dow Jones index falling around 0.2%, yet several biotech stocks performed strongly, reflecting ongoing investor interest and confidence in the sector, which may signal future investment opportunities.
See More
Microbix Launches First Recombinant Antigen Product for COVID-19 Testing
- Recombinant Antigen Launch: Microbix announces the commercial availability of its first recombinant antigen product, the SARS-CoV-2 nucleocapsid protein, marking a significant advancement in synthetic antigen production and expected to enhance its competitiveness in the quality assessment products market.
- Market Demand Response: This recombinant antigen is incorporated into Microbix's Quality Assessment Products (QAPs™), supporting clinical laboratory proficiency testing and addressing the growing market demand for COVID-19 testing, which is anticipated to drive sales growth for the company.
- Expanded Technical Capabilities: By producing recombinant antigens in-house, Microbix not only improves supply chain security but also enhances cost control, thereby strengthening its market position in the clinical laboratory and test manufacturing sectors.
- Financial Performance Boost: In fiscal 2025, Microbix reported total QAPs sales of C$5.6 million, and the introduction of the recombinant antigen is expected to further increase this figure, solidifying its leadership in the global diagnostics industry.
See More
MBX Biosciences to Present Novel Therapies at 44th J.P. Morgan Healthcare Conference
- Conference Participation: Kent Hawryluk, CEO of MBX Biosciences, will present at the 44th J.P. Morgan Healthcare Conference on January 13, 2026, showcasing the company's latest advancements in therapies for endocrine and metabolic disorders, which is expected to attract investor interest.
- Product Pipeline: The company is advancing several novel precision peptide therapies, including MBX 2109, which is preparing for Phase 3 clinical trials targeting chronic hypoparathyroidism, indicating significant market potential.
- R&D Platform: MBX Biosciences focuses on developing innovative therapies for endocrine and metabolic disorders based on its proprietary PEP™ platform, addressing unmet medical needs and positioning the company for future growth.
- Market Opportunities: The company is also developing multiple candidates for obesity, including MBX 4291 in Phase 1, highlighting its potential to secure a significant position in the rapidly growing biopharmaceutical market.
See More
Analyst Target Prices Indicate Potential for Pharmaceuticals ETF
- ETF Upside Potential: The iShares U.S. Pharmaceuticals ETF (IHE) has an implied analyst target price of $96.28 per unit, while trading at $86.15, indicating an 11.76% upside, reflecting market optimism about the ETF's future performance.
- MBX Stock Analysis: MBX BIOSCIENCES INC (MBX) trades at $35.83, with an analyst target price of $60.55, suggesting a potential upside of 69.01%, showcasing investor confidence in its future prospects.
- CRNX Stock Outlook: Crinetics Pharmaceuticals Inc (CRNX) has a current price of $51.32 and an analyst target of $83.46, indicating a 62.63% upside, reflecting positive market sentiment regarding its product and R&D advancements.
- XERS Investment Opportunity: Xeris Biopharma Holdings Inc (XERS) is priced at $7.14, with an analyst target of $11.14, showing a 56.05% upside, indicating analysts' optimism about its growth potential.
See More
MBX Biosciences Advances Obesity Drug Development with Strong Cash Position
- Clinical Trial Progress: MBX's Phase 2 trial demonstrated significant efficacy of canvuparatide in chronic hypoparathyroidism patients, with one-year follow-up data expected in Q2 2026, reinforcing its potential as a best-in-class therapy.
- Obesity Drug Pipeline Expansion: Data from MBX 4291, a dual GLP-1/GIP co-agonist, is anticipated in Q4 2026, showcasing potential for once-monthly dosing aimed at improving tolerability for obesity patients, addressing a critical market need.
- Strong Cash Position: As of December 31, 2025, MBX reported approximately $373.7 million in cash and equivalents, expected to fund operations into 2029, ensuring continued investment in R&D and market expansion.
- New Candidate Nominations: In 2026, MBX plans to nominate two additional obesity candidates, an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist, each designed for once-monthly dosing, further enriching its obesity treatment pipeline.
See More
MBX Biosciences Updates on 2026 Clinical Progress and Strong Cash Position
- Clinical Trial Progress: MBX Biosciences plans to share 12-week data for once-weekly canvuparatide in Q2 2026, which is anticipated to establish it as a best-in-class therapy for chronic hypoparathyroidism, further solidifying its market position in the endocrine sector.
- New Drug Candidate Nominations: The company expects to nominate two new obesity treatment candidates in 2026, including an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist, aimed at addressing diverse patient needs in the obesity market and driving expansion.
- Strong Cash Position: As of December 31, 2025, MBX reported preliminary unaudited cash and cash equivalents of approximately $373.7 million, which is expected to fund operations into 2029, ensuring continued investment in R&D and market expansion.
- Strategic Conference Arrangement: MBX will provide updates on its clinical programs and obesity pipeline at the J.P. Morgan Healthcare Conference on January 13, 2026, showcasing its innovative capabilities and market potential in endocrine and metabolic disorders.
See More
Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release
- Stock Surge: Monte Rosa Therapeutics Inc (NASDAQ:GLUE) shares soared 45.2% to $23.25 after announcing interim data from its Phase 1 clinical study evaluating MRT-8102, indicating strong market confidence in its research progress and potentially attracting more investor interest.
- Acquisition Rumors: Ventyx Biosciences Inc (NASDAQ:VTYX) saw a 37.5% increase to $13.82 following reports that Eli Lilly & Co (NYSE:LLY) is in advanced talks to acquire the company for over $1 billion, which may further drive market interest in biotech stocks.
- Analyst Rating: Erasca Inc (NASDAQ:ERAS) rose 17.1% to $4.25 after Piper Sandler analyst Kelsey Goodwin initiated coverage with an Overweight rating and a price target of $5, reflecting optimism about its future growth potential.
- Market Dynamics: The overall market was mixed, with the Dow Jones index falling around 0.2%, yet several biotech stocks performed strongly, reflecting ongoing investor interest and confidence in the sector, which may signal future investment opportunities.
See More
Microbix Launches First Recombinant Antigen Product for COVID-19 Testing
- Recombinant Antigen Launch: Microbix announces the commercial availability of its first recombinant antigen product, the SARS-CoV-2 nucleocapsid protein, marking a significant advancement in synthetic antigen production and expected to enhance its competitiveness in the quality assessment products market.
- Market Demand Response: This recombinant antigen is incorporated into Microbix's Quality Assessment Products (QAPs™), supporting clinical laboratory proficiency testing and addressing the growing market demand for COVID-19 testing, which is anticipated to drive sales growth for the company.
- Expanded Technical Capabilities: By producing recombinant antigens in-house, Microbix not only improves supply chain security but also enhances cost control, thereby strengthening its market position in the clinical laboratory and test manufacturing sectors.
- Financial Performance Boost: In fiscal 2025, Microbix reported total QAPs sales of C$5.6 million, and the introduction of the recombinant antigen is expected to further increase this figure, solidifying its leadership in the global diagnostics industry.
See More
MBX Biosciences to Present Novel Therapies at 44th J.P. Morgan Healthcare Conference
- Conference Participation: Kent Hawryluk, CEO of MBX Biosciences, will present at the 44th J.P. Morgan Healthcare Conference on January 13, 2026, showcasing the company's latest advancements in therapies for endocrine and metabolic disorders, which is expected to attract investor interest.
- Product Pipeline: The company is advancing several novel precision peptide therapies, including MBX 2109, which is preparing for Phase 3 clinical trials targeting chronic hypoparathyroidism, indicating significant market potential.
- R&D Platform: MBX Biosciences focuses on developing innovative therapies for endocrine and metabolic disorders based on its proprietary PEP™ platform, addressing unmet medical needs and positioning the company for future growth.
- Market Opportunities: The company is also developing multiple candidates for obesity, including MBX 4291 in Phase 1, highlighting its potential to secure a significant position in the rapidly growing biopharmaceutical market.
See More
